Research team finds new adaptive trick used by Staphylococcus bacteria

phys.org | July 12, 2019

In recently published research into the regulatory mechanisms of a disease bacterium often found in the human body, Ohio University Heritage College of Osteopathic Medicine Associate Professor of Bacteriology Erin Murphy, Ph.D., and her team didn't find what they went looking for. What they did find, however, opens more research pathways, suggesting science has more to learn about the tools different bacterial pathogens use to adapt to changes in their environment. Murphy is a member of both the Infectious and Tropical Disease Institute and Ohio's interdisciplinary Molecular and Cellular Biology Program (MCB). She and her research team—including collaborators from Ohio University, Egypt and Germany—were trying to identify a temperature-sensitive mechanism that regulates gene expression in Staphylococcus aureus. This is the well-known bacterium many people carry in their nostrils that sometimes penetrates further into the body, causing harmful infections. As S. aureus moves from the nose to inside the body, its surroundings get warmer. In some bacteria, such a temperature increase triggers changes in gene expression that may better equip the germ to survive in its new environment—which is bad health news for the human whose body the staph has invaded.

Spotlight

Eva Decker, of the university's Faculty of Biology, explained: "We use moss, because, by mass, it has a huge surface area. You can see all the structures and it can clean the dirt particles out of the air. Moss has shoots or spores, and from one of these spores you can grow a new plant. And using these spores we started to cultivate new plants in the laboratory."

Spotlight

Eva Decker, of the university's Faculty of Biology, explained: "We use moss, because, by mass, it has a huge surface area. You can see all the structures and it can clean the dirt particles out of the air. Moss has shoots or spores, and from one of these spores you can grow a new plant. And using these spores we started to cultivate new plants in the laboratory."

Related News

CELL AND GENE THERAPY

Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent ability to evade antibodies highlights the importance of Killer T cells, which can still recognize and eliminate virus-infected cells. Millions among us suffer from inadequate T cell response for various reasons. After two years of the pandemic and witnessing the challenges posed by the ever-evolving virus, we must explore scientific options beyond our current approaches. CTL therapeutics for large patient populations is not an easy undertaking, but Tevogen’s ability to manufacture hundreds of doses from a single donor gives me hope,” Tevogen CEO Ryan Saadi, M.D., M.P.H The granted patent covers Tevogen’s investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T Lymphocytes therapy, TVGN-489, for high-risk COVID-19 patients. The product is currently undergoing a proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials - Tevogen. About TVGN-489 TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong antiviral activity toward SARS-CoV-2 targets in preclinical studies. About Tevogen Bio Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Read More

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop novel cell therapies in January 2019. Under the terms of the agreement, Obsidian is eligible to receive potential future milestone and royalty payments. "We are very interested in exploring innovative approaches to developing engineered cell therapies, including the cytoDRiVE™ platform," said Rupert Vessey, D. Phil., Executive Vice President, Research and Early Development, Bristol Myers Squibb.

Read More

MEDICAL

Controlant now Providing Monitoring and Supply Chain Visibility for Pfizer-BioNTech COVID-19 Vaccine's Global Distribution

Controlant | December 16, 2020

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant is providing to Pfizer to mRNA-based Pfizer-BioNTech COVID-19 vaccine distribution supply chain, the organization is likewise working straightforwardly with the U.S. Government and wellbeing authorities, for example, the Center for Disease Control (CDC), U.S. Division of Health and Human Services (HHS), and stakeholders in Operation Warp Speed, to give nearby observing at U.S. Government-preferred designated vaccination areas to help consistently guarantee coherence during hand-off, actionable communication, and visibility, all through the entirety of the U.S. supply chain journey of the vaccines.

Read More